Hasten Revolutionizes Asia-Pacific Healthcare Marketing Through Strategic Expansion

Hasten Biopharmaceutical Co., Ltd. (“Hasten”) recently achieved a significant milestone in its journey to establishing a robust commercial network across Asia-Pacific. The company completed 70 Marketing Authorization Transfers, solidifying its foothold in Southeast Asia, Australia, Korea, Hong Kong SAR, and Taiwan, Province of China. This achievement signifies the development of a comprehensive pan-Asia-Pacific commercial platform, redefining global expansion standards within the biopharmaceutical industry. Since acquiring the commercial rights to a lineup of branded products in eight Asia-Pacific territories in June 2024, Hasten executed its regional strategy swiftly. Leveraging its expertise in overseas regulatory filings, market expansion, and cGMP compliance audits,…